
|Articles|May 1, 2004
Integrated analysis underlines etanercept efficacy in psoriasis
Washington - Results of a multistudy analysis reinforce the efficacy of subcutaneous etanercept (Enbrel, Amgen) for inducing rapid and sustained improvement in patients with chronic plaque psoriasis, said Kenneth Gordon, M.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
Reviewing the Overarching Umbrella of Psoriatic Disease
5

















